{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:53:33Z","timestamp":1783720413583,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Dr. Kleist Stiftung","award":["Kleist18122021"],"award-info":[{"award-number":["Kleist18122021"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11307-025-02056-7","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:33:08Z","timestamp":1760639588000},"page":"1006-1014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[18F]FDG-PET\/CT Imaging for Response Characterisation of Experimental Melanomas to Anti-PD-L1\/Anti-CTLA-4 Immunotherapy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-360X","authenticated-orcid":false,"given":"Melissa J.","family":"Antons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Kloiber-Langhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Hirner-Eppeneder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Stueckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosel","family":"Oos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix L.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice M.","family":"Heimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2056_CR1","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","volume":"37","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Freeman GJ, McDermott DF (2015) The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma. Clin Ther 37:764\u2013782","journal-title":"Clin Ther"},{"key":"2056_CR2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39:98","journal-title":"Am J Clin Oncol"},{"key":"2056_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704","journal-title":"Annu Rev Immunol"},{"key":"2056_CR4","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 10:727","journal-title":"Am J Cancer Res"},{"key":"2056_CR5","doi-asserted-by":"publisher","first-page":"16824","DOI":"10.1002\/jcp.28358","volume":"234","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad A et al (2019) PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol 234:16824\u201316837","journal-title":"J Cell Physiol"},{"key":"2056_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jtho.2017.11.111","volume":"13","author":"MA Socinski","year":"2018","unstructured":"Socinski MA (2018) Current and emergent therapy options for advanced squamous cell lung cancer. J Thorac Oncol 13:165\u2013183","journal-title":"J Thorac Oncol"},{"key":"2056_CR7","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1158\/1055-9965.EPI-22-0279","volume":"31","author":"DJ Papke Jr","year":"2022","unstructured":"Papke DJ Jr, Lindeman NI, Schrag D, Iorgulescu JB (2022) Underutilization of guideline-recommended mismatch repair\/microsatellite instability biomarker testing in advanced colorectal cancer. Cancer Epidemiol Biomarkers Prev 31:1746\u20131751","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2056_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","volume":"13","author":"JD Wolchok","year":"2008","unstructured":"Wolchok JD, Saenger Y (2008) The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13:2\u20139","journal-title":"Oncologist"},{"key":"2056_CR9","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","volume":"17","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG (2011) Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17:6958\u20136962","journal-title":"Clin Cancer Res"},{"key":"2056_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"2056_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12180","volume":"1291","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD (2013) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 1291:1\u201313","journal-title":"Ann N Y Acad Sci"},{"key":"2056_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-020-01519-1","volume":"15","author":"M Unterrainer","year":"2020","unstructured":"Unterrainer M et al (2020) Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol 15:1\u201315","journal-title":"Radiat Oncol"},{"key":"2056_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/MNM.0b013e3280708ecf","volume":"28","author":"MS Falk","year":"2007","unstructured":"Falk MS (2007) Interpretation, accuracy and management implications of FDG PET\/CT in cutaneous malignant melanoma. Nucl Med Commun 28:273\u2013280","journal-title":"Nucl Med Commun"},{"key":"2056_CR14","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.2214\/AJR.18.19796","volume":"212","author":"Y Sanli","year":"2019","unstructured":"Sanli Y, Leake J, Odu A, Xi Y, Subramaniam R (2019) Tumor heterogeneity on FDG PET\/CT and immunotherapy: an imaging biomarker for predicting treatment response in patients with metastatic melanoma. AJR Am J Roentgenol 212:1318\u20131326","journal-title":"AJR Am J Roentgenol"},{"key":"2056_CR15","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"R-D Seban","year":"2019","unstructured":"Seban R-D et al (2019) Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging 46:2298\u20132310","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2056_CR16","doi-asserted-by":"publisher","first-page":"103044","DOI":"10.1016\/j.critrevonc.2020.103044","volume":"153","author":"C Bisschop","year":"2020","unstructured":"Bisschop C, de Heer E, Brouwers A, Hospers G, Jalving M (2020) Rational use of 18F-FDG PET\/CT in patients with advanced cutaneous melanoma: A systematic review. Crit Rev Oncol Hematol 153:103044","journal-title":"Crit Rev Oncol Hematol"},{"key":"2056_CR17","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","volume":"49","author":"E Lopci","year":"2022","unstructured":"Lopci E et al (2022) Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F] FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging 49:2323\u20132341","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2056_CR18","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2056_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","volume":"80","author":"SM Swetter","year":"2019","unstructured":"Swetter SM (2019) Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 80:208\u2013250","journal-title":"J Am Acad Dermatol"},{"key":"2056_CR20","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","volume":"47","author":"R-D Seban","year":"2020","unstructured":"Seban R-D et al (2020) Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging 47:2301\u20132312","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2056_CR21","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.3390\/cancers13153830","volume":"13","author":"K Kudura","year":"2021","unstructured":"Kudura K et al (2021) Prediction of early response to immune checkpoint inhibition using FDG-PET\/CT in melanoma patients. Cancers 13:3830","journal-title":"Cancers"},{"key":"2056_CR22","doi-asserted-by":"publisher","first-page":"175883592093033","DOI":"10.1177\/1758835920930333","volume":"12","author":"R Jin","year":"2020","unstructured":"Jin R et al (2020) Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. Ther Adv Med Oncol 12:1758835920930333","journal-title":"Ther Adv Med Oncol"},{"key":"2056_CR23","first-page":"V11","volume":"63","author":"M Antons","year":"2024","unstructured":"Antons M et al (2024) Multi-time-point 18F-FDG-PET\/CT for monitoring a combined anti-PD-L1 and anti-CTLA-4 immunotherapy in a murine melanoma model with multiparametric immunohistochemical validation. Nuklearmedizin-NuclearMedicine 63:V11","journal-title":"Nuklearmedizin-NuclearMedicine"},{"key":"2056_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3390\/diagnostics13061041","volume":"13","author":"BP Sorroche","year":"2023","unstructured":"Sorroche BP et al (2023) PD-L1 tumor expression as a predictive biomarker of immune checkpoint inhibitors\u2019 response and survival in advanced melanoma patients in Brazil. Diagnostics 13:1041","journal-title":"Diagnostics"},{"key":"2056_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1387706","volume":"7","author":"M Tucci","year":"2018","unstructured":"Tucci M et al (2018) Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. Oncoimmunology 7:e1387706","journal-title":"Oncoimmunology"},{"key":"2056_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","volume":"125","author":"C Pilard","year":"2021","unstructured":"Pilard C et al (2021) Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response. Br J Cancer 125:927\u2013938","journal-title":"Br J Cancer"},{"key":"2056_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02656-7","volume":"18","author":"S Nisar","year":"2020","unstructured":"Nisar S et al (2020) Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer. J Transl Med 18:1\u201311","journal-title":"J Transl Med"},{"key":"2056_CR28","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2967\/jnumed.116.177493","volume":"57","author":"EB Ehlerding","year":"2016","unstructured":"Ehlerding EB, England CG, McNeel DG, Cai W (2016) Molecular imaging of immunotherapy targets in cancer. J Nucl Med 57:1487\u20131492","journal-title":"J Nucl Med"},{"key":"2056_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1148\/radiol.2018181349","volume":"290","author":"M Nishino","year":"2019","unstructured":"Nishino M, Hatabu H, Hodi FS (2019) Imaging of cancer immunotherapy: current approaches and future directions. Radiology 290:9\u201322","journal-title":"Radiology"},{"key":"2056_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1102\/1470-7330.2012.9013","volume":"12","author":"S Diederich","year":"2012","unstructured":"Diederich S (2012) Imaging beyond RECIST: CT and MRI in molecular therapies. Cancer Imaging 12:347","journal-title":"Cancer Imaging"},{"key":"2056_CR31","doi-asserted-by":"publisher","first-page":"1S","DOI":"10.2967\/jnumed.108.057174","volume":"50","author":"WA Weber","year":"2009","unstructured":"Weber WA (2009) Assessing tumor response to therapy. J Nucl Med 50:1S-10S","journal-title":"J Nucl Med"},{"key":"2056_CR32","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(17)30846-X","volume":"19","author":"JA Beaver","year":"2018","unstructured":"Beaver JA et al (2018) Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US food and drug administration pooled analysis. Lancet Oncol 19:229\u2013239","journal-title":"Lancet Oncol"},{"key":"2056_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","volume":"42","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C et al (2015) Predictive value of early 18 F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging 42:386\u2013396","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2056_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41747-020-00190-1","volume":"4","author":"M Unterrainer","year":"2020","unstructured":"Unterrainer M et al (2020) PET\/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp 4:1\u201313","journal-title":"Eur Radiol Exp"},{"key":"2056_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026608","volume":"12","author":"M Tatsumi","year":"2022","unstructured":"Tatsumi M (2022) Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: comparison to FDG PET. Front Oncol 12:1026608","journal-title":"Front Oncol"},{"key":"2056_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1158\/2326-6066.CIR-14-0118","volume":"3","author":"S Chen","year":"2015","unstructured":"Chen S et al (2015) Combination of 4\u20131BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res 3:149\u2013160","journal-title":"Cancer Immunol Res"},{"key":"2056_CR37","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571","journal-title":"Nature"},{"key":"2056_CR38","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"P-L Chen","year":"2016","unstructured":"Chen P-L (2016) Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6:827\u2013837","journal-title":"Cancer Discov"},{"key":"2056_CR39","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M et al (2018) Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175:998-1013. e1020","journal-title":"Cell"},{"key":"2056_CR40","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","volume":"25","author":"BM Larimer","year":"2019","unstructured":"Larimer BM (2019) The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by granzyme B PET imaging. Clin Cancer Res 25:1196\u20131205","journal-title":"Clin Cancer Res"},{"key":"2056_CR41","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","volume":"24","author":"J Edwards","year":"2018","unstructured":"Edwards J et al (2018) CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-na\u00efve melanoma patients and expand significantly during anti\u2013PD-1 treatment. Clin Cancer Res 24:3036\u20133045","journal-title":"Clin Cancer Res"},{"key":"2056_CR42","doi-asserted-by":"crossref","unstructured":"Banna GL, Cantale O, Bersanelli M, Del Re M, Friedlaender A, Cortellini A, Addeo A (2020) Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.\u00a0Oncol Rev\u00a014(2):490","DOI":"10.4081\/oncol.2020.490"},{"key":"2056_CR43","doi-asserted-by":"publisher","first-page":"175883591880415","DOI":"10.1177\/1758835918804151","volume":"10","author":"N Mu\u00f1oz-Unceta","year":"2018","unstructured":"Mu\u00f1oz-Unceta N, Burgue\u00f1o I, Jim\u00e9nez E, Paz-Ares L (2018) Durvalumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 10:1758835918804151","journal-title":"Ther Adv Med Oncol"},{"key":"2056_CR44","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1021\/acs.molpharmaceut.2c00474","volume":"19","author":"Y Ren","year":"2022","unstructured":"Ren Y (2022) Multimodal imaging response after the singular or combination treatments of vascular endothelial growth factor inhibitor and immune checkpoint inhibitor. Mol Pharm 19:3664\u20133672","journal-title":"Mol Pharm"},{"key":"2056_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00262-003-0474-8","volume":"53","author":"K-M Debatin","year":"2004","unstructured":"Debatin K-M (2004) Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53:153\u2013159","journal-title":"Cancer Immunol Immunother"},{"key":"2056_CR46","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0140-6736(87)90977-9","volume":"330","author":"J Gerdes","year":"1987","unstructured":"Gerdes J (1987) Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin\u2019s lymphomas. Lancet 330:448\u2013449","journal-title":"Lancet"},{"key":"2056_CR47","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/jnci\/djr393","volume":"103","author":"M Dowsett","year":"2011","unstructured":"Dowsett M (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656\u20131664","journal-title":"J Natl Cancer Inst"},{"key":"2056_CR48","first-page":"10235","volume":"8","author":"Y Luo","year":"2015","unstructured":"Luo Y et al (2015) Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med 8:10235","journal-title":"Int J Clin Exp Med"},{"key":"2056_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5301\/jbm.5000183","volume":"31","author":"J-S Pyo","year":"2016","unstructured":"Pyo J-S, Kang G, Sohn JH (2016) Ki-67 labeling index can be used as a prognostic marker in gastrointestinal stromal tumor: a systematic review and meta-analysis. Int J Biol Markers 31:204\u2013210","journal-title":"Int J Biol Markers"},{"issue":"1","key":"2056_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.advms.2015.10.001","volume":"61","author":"R Pezzilli","year":"2016","unstructured":"Pezzilli R (2016) Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): a systematic review. Adv Med Sci 61(1):147\u2013153","journal-title":"Adv Med Sci"},{"key":"2056_CR51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00412-018-0659-8","volume":"127","author":"X Sun","year":"2018","unstructured":"Sun X, Kaufman PD (2018) Ki-67: more than a proliferation marker. Chromosoma 127:175\u2013186","journal-title":"Chromosoma"},{"key":"2056_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.34172\/joddd.2022.024","volume":"16","author":"MH Moltajaei","year":"2022","unstructured":"Moltajaei MH, Mehrbani SP, Motahari P, Rezapour R (2022) Clinicopathological and prognostic value of Ki-67 expression in oral malignant melanoma: a systematic review and meta-analysis. J Dent Res, Dent Clin, Dent Prospects 16:140","journal-title":"J Dent Res, Dent Clin, Dent Prospects"},{"key":"2056_CR53","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/exd.14023","volume":"28","author":"C Weishaupt","year":"2019","unstructured":"Weishaupt C et al (2019) Activation of human vascular endothelium in melanoma metastases induces ICAM-1 and E-selectin expression and results in increased infiltration with effector lymphocytes. Exp Dermatol 28:1258\u20131269","journal-title":"Exp Dermatol"},{"key":"2056_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21873\/anticanres.16141","volume":"43","author":"Y Kimura","year":"2023","unstructured":"Kimura Y et al (2023) 18F-fluorodeoxyglucose positron emission tomography\/computed tomography predicts tumor immune microenvironment function in early triple-negative breast cancer. Anticancer Res 43:127\u2013136","journal-title":"Anticancer Res"},{"key":"2056_CR55","doi-asserted-by":"publisher","first-page":"17068","DOI":"10.1002\/cam4.6350","volume":"12","author":"HY Suh","year":"2023","unstructured":"Suh HY (2023) FDG uptake reflects an immune-enriched subtype of thyroid cancer: clinical implications of imaging-based molecular characterization. Cancer Med 12:17068\u201317077","journal-title":"Cancer Med"},{"key":"2056_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618705","volume":"11","author":"Y-S An","year":"2021","unstructured":"An Y-S (2021) Correlation between 18F-FDG uptake and immune cell infiltration in metastatic brain lesions. Front Oncol 11:618705","journal-title":"Front Oncol"},{"key":"2056_CR57","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0284185113484017","volume":"54","author":"L Jian","year":"2013","unstructured":"Jian L, Zhongmin W, Kemin C, Yunfeng Z, Gang H (2013) MicroPET-CT evaluation of interstitial brachytherapy in pancreatic carcinoma xenografts. Acta Radiol 54:800\u2013804","journal-title":"Acta Radiol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02056-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02056-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:02:31Z","timestamp":1768413751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02056-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2056"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02056-7","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this study, we observed humane principles and respected the welfare of animals. The study was officially approved by the government of Upper Bavaria (ROB-55.2\u20132532.Vet_02-19\u201332) and the authors complied with the ARRIVE 2.0 guidelines. All applicable institutional and national guidelines for the care and use of animals were followed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}